veterinary vaccines, 279–280

vesicular stomatitis virus, 283–286

cell-line selection, 283–284

example of VSV-based vaccines, 285–286

production process of VSV vector, 285

VSV-based COVID-19 vaccine

candidates, 286

VSV-based Ebola vaccine, 285

vesicular stomatitis virus vectored vaccines,

281–286

construction, 281–285

pseudotype, 281–283

as vaccine vector, 283

vesicular stomatitis virus

cell-line selection, 283–284

example of VSV-based vaccines, 285–286

production process of VSV vector, 285

VSV-based COVID-19 vaccine

candidates, 286

VSV-based Ebola vaccine, 285

vesicular stomatitis virus vectored vaccines,

281–286

construction, 281–285

pseudotype, 281–283

as vaccine vector, 283

viral-based vaccines manufacturing--current

challenges, 176–177

viral genome, 19–20

viral genome transcription via intermediates,

20–22

viral infection cycle, 22–28

infection in eukaryotic host, 24–28

lysogenic cycle, 23–24

lytic cycle, 22–23

viral quantification methods, 213–217

immuno-based assay, 213–215

particle counters, 215–217

viral vaccine design, 6–8

virology, 17–34

virus characteristics, 18

virus concentration/chromatography, 184–188

virus evolution/classification, 18–19

virus-host interaction, 28–32

components of host cell interacting with viral

elements, 29–30

disease occurrence, 31–32

key elements of viral infection, 31

types of infection, 29–31

318

Index